CPT1A and invasive ductal breast carcinoma: Relative to in situ cancer cases (training set: 31.17 ± 18.35 ng/mL; test set: 31.20 ± 25.37 ng/mL), invasive ductal carcinoma cases exhibited higher CPT1A levels (training set: 41.21 ± 36.66 ng/mL, p < 0.001; test set: 37.90 ± 42.91 ng/mL, p < 0.001; Fig. S3).